GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Waverley Pharma Inc (TSXV:WAVE) » Definitions » Equity-to-Asset

Waverley Pharma (TSXV:WAVE) Equity-to-Asset : -1.19 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Waverley Pharma Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Waverley Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$-1.14 Mil. Waverley Pharma's Total Assets for the quarter that ended in Dec. 2023 was C$0.95 Mil. Therefore, Waverley Pharma's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -1.19.

The historical rank and industry rank for Waverley Pharma's Equity-to-Asset or its related term are showing as below:

TSXV:WAVE' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.19   Med: 0.59   Max: 0.76
Current: -1.19

During the past 8 years, the highest Equity to Asset Ratio of Waverley Pharma was 0.76. The lowest was -1.19. And the median was 0.59.

TSXV:WAVE's Equity-to-Asset is ranked worse than
93.09% of 1562 companies
in the Biotechnology industry
Industry Median: 0.67 vs TSXV:WAVE: -1.19

Waverley Pharma Equity-to-Asset Historical Data

The historical data trend for Waverley Pharma's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Waverley Pharma Equity-to-Asset Chart

Waverley Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.65 0.59 0.49 0.41 -1.19

Waverley Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.30 0.23 0.09 -1.19

Competitive Comparison of Waverley Pharma's Equity-to-Asset

For the Biotechnology subindustry, Waverley Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Waverley Pharma's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Waverley Pharma's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Waverley Pharma's Equity-to-Asset falls into.



Waverley Pharma Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Waverley Pharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-1.137/0.952
=-1.19

Waverley Pharma's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-1.137/0.952
=-1.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Waverley Pharma  (TSXV:WAVE) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Waverley Pharma Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Waverley Pharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Waverley Pharma (TSXV:WAVE) Business Description

Traded in Other Exchanges
Address
1250 Waverley Street, Suite 4, Winnipeg, MB, CAN, R3T 6C6
Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics that focuses on oncology. The company products pipeline includes Capecitabine and Temozolomide, among others.
Executives
Albert David Friesen 10% Security Holder, Director, Senior Officer